Fastcompany·2026-03-09 15:27Core Insights - Hims & Hers Health's stock price has surged following the announcement of a partnership with Novo Nordisk to sell GLP-1 weight-loss drugs, including Wegovy [1] - The partnership marks a significant turnaround in the relationship between Hims & Hers and Novo Nordisk, which was contentious just a month prior [1] Company Developments - Hims & Hers has confirmed the agreement with Novo Nordisk, indicating a strategic move to capitalize on the growing market for GLP-1 medications in the US [1] - Andrew Dudum, CEO of Hims & Hers, expressed optimism about the growth opportunities presented by the expanding range of branded GLP-1 medications [1] Market Reaction - The stock price increase of Hims & Hers reflects investor confidence in the potential success of the partnership with Novo Nordisk [1] - The announcement is expected to have a positive impact on Hims & Hers' market position and revenue streams [1]